IOV-2001 not checked

Iovance Biotherapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.”In the company’s words, NCT04155710 on ClinicalTrials.gov
Tested for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Main trialPhase 1
“This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.”In the company’s words, NCT04155710 on ClinicalTrials.gov
Other names
Autologous PBL

Other drugs for Chronic Lymphocytic Leukemia

All 64 drugs for Chronic Lymphocytic Leukemia

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 11 Nov 2024 Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IOV-2001

Following is part of Solo: you see every change to IOV-2001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in